Alkermes trading temporarily halted by Nasdaq

Alkermes announced that Nasdaq has temporarily halted trading of the company’s ordinary shares. The joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. FDA, will meet today to review the company’s New Drug Application for ALKS 5461. ALKS 5461 is a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder in patients with an inadequate response to standard antidepressant therapies.
https://thefly.com/landingPageNews.php?id=2815209